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Although highly active antiretroviral therapy (HAART) has converted HIV into a chronic disease, a reservoir of HIV latently
infected resting T cells prevents the eradication of the virus from patients. To achieve eradication, HAARTmust be combined
with drugs that reactivate the dormant viruses. We examined this problem in an established model of HIV postintegration la-
tency by screening a library of small molecules. Initially, we identified eight molecules that reactivated latent HIV. Using them as
templates, additional hits were identified by means of similarity-based virtual screening. One of those hits, 8-methoxy-6-
methylquinolin-4-ol (MMQO), proved to be useful to reactivate HIV-1 in different cellular models, especially in combination
with other known reactivating agents, without causing T-cell activation and with lower toxicity than that of the initial hits. Inter-
estingly, we have established that MMQO produces Jun N-terminal protein kinase (JNK) activation and enhances the T-cell re-
ceptor (TCR)/CD3 stimulation of HIV-1 reactivation from latency but inhibits CD3-induced interleukin-2 (IL-2) and tumor ne-
crosis factor alpha (TNF-) gene transcription. Moreover, MMQO prevents TCR-induced cell cycle progression and
proliferation in primary T cells. The present study documents that the combination of biological screening in a cellular model of
viral latency with virtual screening is useful for the identification of novel agents able to reactivate HIV-1. Moreover, we set the
bases for a hypothetical therapy to reactivate latent HIV by combiningMMQOwith physiological or pharmacological TCR/CD3
stimulation.
HIV-infected individuals successfully treated with antiretrovi-ral therapy (ART) control viremia down to undetectable lev-
els. Nevertheless, viremia reemerges rapidly after the interruption
of treatment, which is consistent with the existence of a latent viral
reservoir. This reservoir consists mainly of long-lived latently in-
fected resting memory CD4 T cells (16, 28). The absence of viral
protein expression shields latently infected cells from the immune
system. Latently infected cells can be maintained for years by cel-
lular quiescence. Antigen stimulation or cytokine induction reac-
tivates the latent provirus and leads to viral replication and rein-
fection. This reservoir prevents the total eradication of the virus.
As a result, the infection is converted into a chronic disease. To
achieve HIV eradication from infected patients, ART might have
to be combined with drugs that reactivate the dormant viruses
(72).
Latently infected cells contain replication-competent provirus
blocked at the transcriptional level by effective and reversible si-
lencing (molecular mechanisms of HIV latency are reviewed in
references 3, 17, 18, and 45). HIV transcription depends on cellu-
lar factors (Sp1, NF-B,NFAT, and others) in addition to the viral
Tat transactivator, and consequently the activity of the HIV pro-
moter is tightly linked to the level of activation of its host cell. A
suboptimal cellular environment for HIV expression at the tran-
scriptional or posttranscriptional level collaborates to maintain
the latent state.
The transcription factor Tat binds an RNA element (TAR) at
the 5= end of the viral transcript. Its main role is to recruit the
P-TEFb complex to the long terminal repeat (LTR) to promote
efficient elongation (40, 58). Tat is absent from infected cells until
inefficient transcription from the HIV promoter (depending on
host cell factors) allows some synthesis of this viral protein. After
Tat is produced, HIV transcription enters a second,more efficient
phase. In latently infected cells, HIV transcription is blocked at the
initial phase, Tat is absent, and chromatin imposes a barrier to the
clearance of the preinitiation complex and polymerase progres-
sion. Chromatin plays an essential role in the transcriptional reg-
ulation of HIV (61, 64). Key regulatory nucleosomes are posi-
tioned around the transcription start site of HIV when the
promoter is inactive and are acetylated or remodeled upon acti-
vation (50, 75). Previous models of HIV latency, cell lines ACH2
and U1, harbored proviruses with mutations in their Tat-TAR
transcriptional axis, strengthening the concept that transcription
inhibition is key to establishing andmaintaining HIV latency (26,
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27). Thus, the lack of specific host factors, a defective Tat-TAR
axis, and a repressive chromatin environment could contribute to
postintegration latency.
HIV transcription is determined by the site of integration in
the human genome (39). The survival of the infected cell to allow
conversion to the resting state may require integration at a
genomic site unfavorable for HIV transcription. Rare latent infec-
tion has been associated with provirus integration at regions of
constitutive heterochromatin, such as centromeric alphoid re-
peats, gene deserts, or introns of very highly expressed genes (35,
38, 49). The silenced HIV promoter has been associated with re-
pressive epigenetic marks, histone deacetylases and methyltrans-
ferases, heterochromatin proteins, and CpG methylation (5, 24,
30, 37, 41, 80). Transcriptional interference has been proposed as
the cause of the silencing of HIV integrated at active genes (33, 48,
49). Chromatin reassembly factors traveling with the machinery
transcribing a host gene where a latent HIV is integrated partici-
pate in this repressing phenomenon (31).
Several agents or chemical compounds stimulate transcription
from the HIV-1 promoter and, consequently, reactivate latently
integrated viruses (reviewed in reference 18). Treatment with sin-
gle cytokines, such as interleukin-2 (IL-2) or IL-7, or in different
combinations, reactivate latent HIV-1 in resting CD4 T cells
obtained from ART-treated patients or in a chronically infected
cell line (8, 15, 47, 60, 78). Tumor necrosis factor alpha (TNF-)
stimulates HIV-1 reactivation in U1 cells but not in resting CD4
T cells unless combinedwith IL-6 and IL-2 (14, 75). The drawback
of treatments with cytokines is that they promote the global acti-
vation of resting T cells, decreasing the immunologicalmemory of
the organism. Mitogenic phorbol esters such as phorbol-12-
myristate-13-acetate (PMA), as well as the non-tumor-promoting
phorbol ester prostratin, also activate the dormant HIV-1 pro-
moter through the activation of protein kinase C (PKC) and, ul-
timately, NF-B pathways (7, 8, 43, 75, 79). In addition to PKC,
the stimulation of the nuclear factor of activatedT cells (NF-AT) is
also a key pathway leading to HIV-1 activation.
Histone deacetylase (HDAC) inhibitors, such as trichostatin A
(TSA) or butyric acid, were described earlier as activators of the
dormantHIV-1 promoter in chronically infected cell lines by pro-
moting chromatin remodeling at the proviral promoter (74).
Later, valproic acid was extensively used to investigate the poten-
tial of HDAC inhibitors for reactivating HIV-1 in many different
model systems or even in volunteer patients, with contradictory
results (46, 65, 69, 84). HDAC inhibitors do not globally activate
resting T cells but may have general effects on transcription. Re-
cently, new HDAC inhibitors, more potent and selective, were
developed and tested on HIV-1 reactivation, including SAHA
(suberoylanilide hydroxamic acid) (1, 12, 20, 53, 83). Combining
nonmitogenic phorbol esters, such as prostratin, with HDAC in-
hibitors has a synergistic effect onHIV-1 reactivation and could be
the basis of future therapies to eradicate the virus from patients
(62). Additionally, inhibitors of other chromatin modifiers in-
volved in HIV-1 repression could enter into play, such as inhibi-
tors of histone or DNA methylation (30, 37, 41).
Using amodel of HIV postintegration latency consisting of the
infection of Jurkat cells with a green fluorescent protein (GFP)-
encoding HIV minigenome and selecting for reversible silent in-
tegrations (38), we searched for new chemical agents that reacti-
vate latent HIV-1. Initially, eight molecules were identified from a
library of 6,000 small molecules, and other derivative molecules
were proposed by applying virtual screening with computational
tools and were validated in the latency cellular model. One partic-
ular drug, 8-methoxy-6-methylquinolin-4-ol (MMQO), has been
useful to reactivate HIV in different cellular models, especially in
combinationwith TNF- or other known reactivating agents. Ad-
ditionally, we explored the pathway that could be involved in the
activation of the silencedHIV promoter byMMQO.MMQOpro-
duced Jun N-terminal protein kinase (JNK) activation and T-cell
receptor (TCR)/CD3 costimulation to activate the NF-B and the
extracellular signal-regulated kinase (ERK) pathways. Interest-
ingly, MMQO prevents TCR-induced cell proliferation in pri-
mary T cells.
MATERIALS AND METHODS
Cell lines, culturing conditions, and cell treatments.We used an estab-
lished model of HIV-1 latency based on the infection of Jurkat T cells at a
low multiplicity of infection (MOI) with HIV-derived particles contain-
ing the minigenome carried by plasmid pEV731 (LTR-Tat-internal ribo-
some entry site [IRES]-GFP-LTR) (38). Briefly, GFP-negative cells were
treated with TNF-, and resulting GFP-positive, latently infected cells
were isolated (latent pool), and clones were generated from single cells.
Clones J-Lat H2, A1 and A2 (38), E27 (31), and Jurkat-LAT-GFP clone 8
(52) have been described elsewhere. Additionally, clones J-Lat 6.3 and
15.4, generated similarly with a full-length GFP-encoding HIV-1 vector
(HIV-R7/E/GFP), were described already (38).
Jurkat-derived clones, ACH2 and U1 cells, were grown in RPMI 1640
medium (Gibco) supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin at 37°C
under a 5%CO2 atmosphere. HEK293T andHeLa cells were grown under
the same conditions as those of Jurkat cells in Dulbecco’s modified Eagle
medium (Gibco) supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin.
When indicated, cells were treated with 10 nMPMA (Sigma-Aldrich),
400 nM TSA (Sigma-Aldrich), 10 ng/ml TNF- (Sigma-Aldrich), 2 M
prostratin (LC Laboratories), 5 M 5-aza-2=deoxycitidin (5-azadC;
Sigma-Aldrich), or 10 mM hexamethylene bisacetamide (19) (HMBA;
Sigma-Aldrich), unless other concentrations are indicated in the figure
legends. Similarly, cells were stimulated with immobilized -CD3mono-
clonal antibody (MAb) (1 g/ml; clone OKT3) or soluble -CD28 MAb
(0.5g/ml; clone 15E8). 5-azadC was added 24 h before other treatments
(preincubation). Details of treatment with other drugs are in particular
figure legends.
Culturing of PBMCs from patients. Peripheral blood mononuclear
cells (PBMCs) were isolated from buffy coats from aviremic, highly active
antiretroviral therapy (HAART)-treated HIV-1 patients (Hospital Clínic,
Barcelona, Spain) by centrifugation through a Ficoll-Hypaque gradient
(Sigma Chemical Co., St. Louis, MO). Primary cells were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin at 37°C
under a 5% CO2 atmosphere. These cell cultures were treated as soon as
they were seeded withMMQO or other drugs, as indicated in each exper-
iment, without phytohemagglutinin addition. All of the patients gave in-
formed written consent, and this study was reviewed and approved by the
Institutional Ethical Committee board of Hospital Clínic (Barcelona,
Spain).
Drug screening. For screening a library of 6,000 small molecules
(Chembridge, San Diego, CA), each compound was added at 40 M to
5 104 J-Lat A2 cells in 200 l of medium in 96-well plates. After 24 h of
incubation, the percentage of GFP-expressing cells was determined by
flow cytometry. Each plate contained wells with PMA (10 nM) or TSA
(400 nM) as a positive control for HIV-1 reactivation.
Flow cytometry analysis and sorting. GFP fluorescence was mea-
sured in a Cytomics FC500MPL cytometer (Beckman Coulter, Fullerton,
CA). A two-parameter analysis was used to distinguish GFP-derived flu-
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orescence from the background. Fluorescence was represented in a loga-
rithmic scale. Cell sorting was carried out with the Moflo high-speed
sorter (Dako-Cytomatin, Fort Collins, CO).
Cell cycle analysis. Cells were harvested by centrifugation, washed
twice with phosphate-buffered saline (PBS), resuspended in PBS, and
fixed in 70% ethanol at 20°C overnight. Fixed cells were washed three
times with PBS, treated with RNase A (1 mg/ml) at 37°C for 1 h, and
stained with propidium iodide (0.1 mg/ml). DNA content was deter-
mined on aCoulter Epics XL cytometer (BeckmanCoulter Inc., Fullerton,
CA) and analyzed with MultiCycle AV (Phoenix Flow Systems) for peak
definitions corresponding to the different cell cycle phases.
Apoptosis monitoring. Cultured cells were labeled with annexin V
conjugated to the red-sensitive dye CF647 and 7-aminoactinomycin (7-
AAD), which were included in the FlowCellect annexin red kit (Milli-
pore), by following the manufacturer’s instructions and were analyzed in
a Gallios cytometer (Beckman Coulter Inc., Fullerton, CA).
Human T-cell proliferation assays. PBMCs from healthy adult vol-
unteer donors were isolated by the centrifugation of venous blood on
Lymphoprep density gradients (Axis-Shield PoC, Oslo, Norway). Cells
(105) were cultured in triplicate in 96-well round-bottom microtiter
plates in 200 l of complete medium and stimulated with staphylococcal
enterotoxin B (SEB) (1 g/ml) (Sigma Chemical Co., St. Louis, MO) in
the presence or absence ofMQQO as indicated. The cultures were carried
out for 3 days and pulsed with 0.5 Ci [3H]thymidine (TdR)/well (MP
Biomedicals, Irvine, CA) for the last 12 h of culture. Radioactivity incor-
porated into DNA was measured by liquid scintillation counting.
Infectivity assay. Viral infectivity from treated ACH2 cell culture su-
pernatant fluids was measured using TZM-bl indicator cells harboring an
integrated LTR-luciferase reporter system as described elsewhere (54).
Viruses were quantified by determining the concentration of p24 in the
supernatant with an antigen (Ag) capture assay (enzyme-linked immu-
nosorbent assay [ELISA]; Innogenetics NV, Ghent, Belgium).
RNA extraction, reverse transcription-PCR (RT-PCR), and quanti-
tative PCR (qPCR) for expression analysis. Total RNA was extracted
using High Pure RNA isolation (Roche) according to the manufacturer’s
instructions. cDNA was obtained from 100 ng of total RNA using Super-
Script VILO cDNA synthesis (Invitrogen). The indicated gene products
were analyzed by PCR with specific oligonucleotides, followed by visual-
ization in agarose gels. Where indicated, the quantification of gene prod-
ucts was performed by real-time PCR using LightCycler 480 SYBR green I
master mix (Roche, Indianapolis, IN). Each value was corrected by hu-
man glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ex-
pressed as relative units. Sequences of oligonucleotides used for real-time
PCR were the following: 5=LTR (R-gag) forward (AGTAGTGTGTGCCC
GTCTGT) and reverse (TCGCTTTCAGGTCCCTGTTCG); Tat forward
(CAAAAGCCTTAGGCATCTCCT) and reverse (CCACCTTCTTCTTC
GATTCCT); GFP forward (GAAGCAGCACGACTTCTTCAA) and re-
verse (GCTTGTCGGCCATGATATAGA); and 3=LTR (U3) forward (AT
CCACTGACCTTTGGATGG) and reverse (GTACTCCGGATGCAGCT
CTC) (31).
Transient transfections and luciferase assays. Jurkat cells were trans-
fected with the indicated plasmids using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer’s recommendations and
treated as indicated. For the luciferase assays, the cells were washed twice
in PBS and lysed in 25 mM Tris-phosphate, pH 7.8, 8 mMMgCl2, 1 mM
dithiothreitol (DTT), 1%Triton X-100, and 7% glycerol during 15min at
room temperature in a horizontal shaker. After centrifugation, the super-
natant was used to measure luciferase activity using an Autolumat LB
9510 (Berthold) by following the instructions of the luciferase assay kit
(Promega, Madison, WI).
Protein extraction, gel electrophoresis, and immunoblotting. Jurkat
cells (106 cells/ml) were stimulated with-CD3 (1g/ml) together with 1
g protein A from Staphylococcus aureus for cross-linking and MMQO
during 15min. Cells were then washed with PBS and proteins extracted in
50l of lysis buffer (20mMHEPES, pH 8.0, 10mMKCl, 0.15mMEGTA,
0.15 mM EDTA, 0.5 mM Na3VO4, 5 mM NaF, 1 mM DTT, 1 g/ml
leupeptin, 0.5 g/ml pepstatin, 0.5 g/ml aprotinin, and 1 mM phenyl-
methylsulfonyl fluoride [PMSF]) containing 0.5% NP-40. Protein con-
centration was determined by the Bradford assay (Bio-Rad, Richmond,
CA), and 30 g of protein was boiled in Laemmli buffer and electropho-
resed in 10% SDS-polyacrylamide gels. Separated proteins were trans-
ferred to nitrocellulose membranes (0.5 A at 100 V; 4°C) for 1 h. Blots
were blocked in Tris-buffered saline (TBS) solution containing 0.1%
Tween 20 and 5% nonfat dry milk overnight at 4°C, and the immunode-
tection of specific proteins was carried out with primary antibodies using
an ECL system (GE Healthcare). The antibodies anti-phospho-IB
(ser32/ser36), anti-phospho-p65 (ser536), and phospho-ERK12
(Tyr204) were from Santa Cruz Biotechnology (Santa Cruz, CA), and
antibodies against anti-phospho-JNK12 (Thr183/Tyr185) and anti-
phospho-p38 (Thr180/Tyr182) were from Cell Signaling (Danvers, MA).
TheMAb anti--tubulin was purchased from Sigma Co. (St. Louis, MO).
Virtual screening. Similarity-based virtual screening is based on en-
coding chemical structures using some sort of mathematical descriptors.
In this work, three types of two-dimensional descriptors were used,
namely, pharmacophoric fragments (PHRAG), feature-pair distributions
(FPD), and Shannon entropy distributions (SHED), each one of them
characterizing chemical structures with a different degree of fuzziness and
thus complementing each other in terms of structural congenericity and
hopping abilities. PHRAG are all possible fixed-length segments of five
atom features that can be extracted from the topology of a molecule. In
contrast, FPD capture the overall spreading of pairs of atom-centered
features at different predefined bond lengths. Finally, SHEDquantifies the
variability within all possible FPD using the concept of Shannon entropy.
Detailed definitions can be found elsewhere (34, 77).
When using PHRAG and FPD, the similarity between two molecules
corresponds to the overlapping fraction of their respective profiles,
whereas with SHED, Euclidean distances are calculated instead (77). The
biological relevance of the similarity and distance values obtained with
these descriptors was assessed on their ability to discriminate active from
random compounds for all targets chemically represented in publicly
available sources. As a result of this validation analysis, compounds with
similarity values of greater than 0.76 and 0.87 for PHRAG and FPD, re-
spectively, and below a distance value of 0.52 for SHEDwere considered to
be within the applicability domain (OAD) of these descriptors (77).
RESULTS
Screeningmolecules that reactivateHIV-1 from latency in an in
vitro cellular model. Using a cell line containing a latent HIV-
based retroviral vector (clone J-Lat A2 [38]), we screened a library
of 6,000 small molecules (purchased from Chembridge, San Di-
ego, CA). Viral expression was monitored by GFP expression in a
flow cytometer. Eight compounds were identified that reproduc-
ibly lead to an induction of HIV expression as measured by in-
creased GFP expression (data not shown). Six of the hits were
grouped in two classes according to chemical similarities. Class 1
contains three molecules with a common quinolin-8-ol structure.
Class 2 molecules share an acyl hydrazone functionality. Hits 4
and 1 were chosen for further analysis as representatives of class 1
and 2 compounds, respectively (Fig. 1A; see Fig. S1A in the sup-
plemental material). A dose-response experiment on a heteroge-
nous population of latently infected cells (J-Lat pool) showed that
maximal activation was achieved with 40 to 80 M both com-
pounds (Fig. 1B). This result indicated that the ability of these
agents to promote HIV-1 reactivation involved different latent
integration events and was not restricted to one particular cell
clone. This was confirmed by testing the reactivation of J-Lat
clones H2, A1, and E27, which were previously described (31, 38)
to harbor the provirus in different genome environments: centro-
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meric alphoid repeats, gene deserts, and gene introns, respectively
(data not shown). Nonetheless, these agents were deleterious to
cell viability, as analyzed by flow cytometry (Fig. 1B and C). Hit 1
was less toxic than hit 4 and produced a better reactivation of the
latent pool.
Because of the deleterious effect of the agents obtained so far,
we next used different methods to search for derivatives with in-
creased reactivating activity and/or lower cell toxicity. We tested
49 compounds (Chembridge) with various permutations of the
R1 to R5 groups of class 1 hits for their ability to reactivate latent
HIV in J-Lat cells (data not shown). This analysis identified nine
new active compounds closely related to hits 4, 7, and 8 (see Fig.
S1B in the supplemental material). This analysis demonstrated
that both R3 and R5 could be replaced while conserving biological
activity and cell toxicity.
Virtual screening identifies MMQO as a novel compound
that reactivates HIV-1 from latency with no cell toxicity. An ef-
ficient, cost-effective strategy to access a significantly larger por-
tion of chemical space is to use computational tools to virtually
screen the commercial catalogues of chemical vendors, from
which selected numbers of molecules are purchased for experi-
mental testing. In cases where target information is missing but
bioactive molecules are known, ligand-based approaches to vir-
tual screening are the best option (25). Accordingly, a collection of
7.5 million unique compounds available commercially was rank
ordered by similarity against the eight hits identified above (2).
The list of top-rankingmoleculeswas further filtered using criteria
based on cost and availability to optimize resources and vendors.
A priority list of 43 compounds was finally selected for purchase
from just three different chemical providers (Chembridge, Enam-
ine, and Specs). Upon reception, testing for the reactivation of
HIV-1 in the J-Lat pool led to the identification of 3 additional
hits (percentage of GFP-expressing cells, 4). One of those,
8-methoxy-6-methylquinolin-4-ol (MMQO), was particularly
active (Fig. 2A). MMQO resembles class 1 initial hits, but it con-
tains an OH group at position 4 instead of 8. On a dose-response
curve,MMQOwas active at concentrations of up to 320M,with
a calculated 50% effective concentration (EC50) close to 80 M
(Fig. 2B). The maximal reactivation potential at 24 h in the J-Lat
pool was higher than that with hits 1 and 4, andmore importantly,
the toxicity was greatly reduced. No effect on cell viability was
observed at concentrations of up to 80 M, the concentration
chosen for further analysis.
The effect of MMQO on cell proliferation was further studied
and compared to the initial hits by the propidium iodide staining
of cells treated for 36 h and followed by cell cycle analysis by flow
cytometry. MMQO produced a slight increase in the proportion
of cells in theG1 phase of the cycle (Fig. 2C andD). In contrast, the
cell cycle profile was clearly altered in cells treated with hit 1 or 4,
including the accumulation of cells in sub-G1, which is indicative
of cell death. To further compare consequences of these com-
pounds on cell viability, treated cells were stained with annexin V
and 7-AAD. The hits produced an increased proportion of cells in
early or late apoptosis (Fig. 2E).
Similarly to the initial hits,MMQO reactivated latent HIV-1 in
different genomic contexts, including active genes (J-Lat E27 and
A2) and centromeric alphoid repeats (J-Lat H2), with no cell tox-
icity (Fig. 3A).
We next analyzed whether MMQO induced HIV-1 expres-
sion at the transcriptional level. To determine if MMQO was
acting through the HIV-1 promoter, we analyzed its effect on
an HIV-1 promoter reporter assay upon transient transfection
into 293T cells. MMQO activated the LTR-luciferase reporter
as efficiently as other HIV inducers, such as TNF-, PMA, or
TSA (Fig. 3B). Further, we performed quantitative PCR on
synthesized cDNA generated from J-Lat E27 cells left untreated
or treated with MMQO. In a time course experiment, the in-
crease in HIV-1 mRNA was detected as early as 2 h after
MMQO addition. At 12 h, HIV-1 expression was increased ca.
12-fold, which is lower than the induction that was observed
FIG 1 Screening of molecules that reactivate HIV from latency in an in vitro
cellular model. (A) Chemical structures of active compounds identified in a
screening for HIV activation. Upon screening a library of 6,000 small mole-
cules using a cell line containing a latent HIV-based retroviral vector (J-Lat
clone A2), eight compounds were identified that reproducibly lead to an in-
duction of HIV expression. Six of these compounds were grouped into two
families according to their structural similarity, classes 1 and 2.Hits 4 and 1 are
representative of these classes 1 and 2, respectively. (B) Dose response of hits 1
and 4. Cells from the J-Lat heterogeneous population were incubated with
increasing concentrations of drug for 24 h and analyzed by flow cytometry.
HIV-GFP reactivation is reported as the percentage of GFP-expressing cells
(%GFP). Cell viability was measured by flow cytometry gating on the live
population at the forward scatter (FSC) and side scatter (SSC) plot. An exam-
ple is shown in panel C.
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with control treatments with PMA or TNF- (Fig. 3C). To
explore whether MMQO induced initiation or enhanced elon-
gation, four amplicons covering the HIV-1 minigenome tran-
script from the 5=LTR to 3=LTR were used: 5=LTR (R-gag), Tat,
GFP, and 3=LTR (U3). Any of these primer pairs distinguished
between spliced and unspliced transcripts due to the nature of
the minimal HIV-1 minigenome in J-Lat cells (Fig. 3D). To
compare different amplicons, the amplification of cDNA was
corrected by the amplification of genomic DNA with the same
sets of primers. MMQO treatment enhanced the expression of
all HIV-1 regions by approximately one order of magnitude
(Fig. 3D). A noted decrease of transcription along the HIV
minigenome at the basal and induced conditions was observed
not only in J-Lat E27 but also in other clones and in the latent
pool (data not shown), and this has been described before (31).
This suggests that latency in J-Lat cells is partially produced by
a block in the elongation of HIV transcripts. MMQO seems to
stimulate transcription initiation instead of being able to spe-
cifically overcome the elongation block. This is similar to the
effect of stimulation with TNF- reported before (31).
Synergistic activation of HIV-1 expression by combination
ofMMQOwith small molecules that reactivate latent virus.We
next compared the abilities of MMQO, other agents, and combi-
nations of them to reactivate latent HIV-1 in J-Lat E27 cells. Be-
cause the percentage of GFP-positive cells approaches 100%upon
strong reactivation by combined agents, data alsowere reported as
mean fluorescence intensity (MFI). MMQO was less active than
PMA, TNF-, prostratin, or HMBA, and its activity was similar to
that of TSA (Fig. 4A and B). When combined, MMQO showed
synergy with PMA, TNF-, and prostratin and only additive ef-
fects with HMBA and TSA. MMQO could further stimulate the
reactivating ability of combinations such as PMA with TNF or
PMAwith TSA. The synergistic effect ofMMQO and other agents
on the reactivation of latentHIV-1was observed in all J-Lat clones
tested, including latent integrations at centromeric alphoid re-
peats (Fig. 4C, J-Lat H2).
Interestingly, the synergism between PMA and MMQO also
was observed at suboptimal doses of both drugs, as low as 15 to 40
MMMQO and 0.3 to 1 mM PMA (Fig. 4D). Synergistic activa-
tion suggests that the two agents use different pathways unless
FIG 2 Virtual screening identifies MMQO as a novel compound that reactivates HIV from latency with no cell toxicity. (A) A library of 43 small molecules (A2
to A44) obtained by virtual screening for compounds pharmacophorically related to the initial hits was purchased and tested for HIV reactivation in a J-Lat
heterogeneous cell population.Drugswere added to cells at 40Mfor 48 h, and the percentage ofGFP-expressing cells (%GFP)wasmeasured by flow cytometry.
The chemical structure of the positive-hit 8-methoxy-6-methylquinolin-4-ol (MMQO) is indicated. (B) Dose response of MMQO. Cells from the J-Lat
heterogeneous population were incubated with increasing concentrations ofMMQO for 24 h and analyzed by flow cytometry. HIV-GFP reactivation is reported
as a percentage of GFP-expressing cells (%GFP) andmean fluorescence intensity (MFI). Cell viability wasmeasured on the FSC-SSC plot as described for Fig. 1C.
Data are represented as means standard errors of the means (SEM) (n 3). (C and D) Cell cycle profile of cells treated with reactivating hits. Jurkat cells were
treated for 36 h with MMQO, hit 1, or hit 4 at 40 M or were maintained untreated as a mock control, followed by propidium iodide staining and the flow
cytometry analysis of the proportion of cells in each cell cycle phase. The percentage of cells in sub-G1, G1, S, and G2/M phases is shown in panel D. Data are
represented asmeans SEM (n 3). (E) Hits 1 and 4, but notMMQO, produce cell death. HeLa cells were treated for 16 h withMMQO, hit 1, or hit 4 at 80M
or were maintained untreated as a mock control, followed by annexin V-CF647 and 7-AAD staining and the flow cytometry analysis of the proportion of cells in
each staining gate. The percentage of cells in early (annexin-positive) or late (annexin-positive plus 7-AAD-positive) apoptosis is shown. Data are represented as
means SEM (n 3).
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they are used at suboptimal concentrations. To explore whether
MMQO’s effect onHIV-1 reactivation was equivalent to the effect
of PMA, TNF-, HMBA, or TSA, we performed experiments of
saturation with one of the agents to see if the other was still active.
In a reactivation experiment with clone J-Lat E27, when the con-
centrations of TNF- or PMA were increased until saturation,
MMQO still showed a clear synergistic effect that further in-
creased HIV-1 reactivation (Fig. 4E). Despite the high concentra-
tions of agents used, cell viability was not greatly compromised
(data not shown). Nonetheless, high concentrations of HMBA or
TSA (more than 10 or 400 mM, respectively) were highly toxic,
and these experiments were not conclusive. Instead, we used in-
creasing concentrations of MMQO up to 150 M, close to satu-
ration, and observed that the addition of suboptimal concentra-
tions of HMBA or TSA was still stimulatory (Fig. 4F) despite the
associated cell toxicity (data not shown). Taken together, our re-
sults indicate thatMMQO synergizes with other known activating
agents on the reactivation of latent HIV-1 in the J-Lat model and
also suggest that its cellular target is different from the known
targets for these compounds, i.e., protein kinase C (PMA), TNF
receptor signaling (TNF-), histone deacetylases (TSA), and
P-TEFb release (HMBA).
MMQO, which was obtained by virtual screening from the
initial hits, was chemically closer to class 1 than to class 2 hits. To
explore whetherMMQOand hits 1 and 4 synergize, we performed
a dose response curve with increasing concentrations of these hits
in the absence or presence of MMQO (Fig. 4G). MMQO syner-
gized with both compounds, more notably with hit 1 (class 2).
This suggested that MMQO and class 2 hits have different cellular
targets to promote HIV-1 reactivation. In a different experiment,
hits 1 and 4 enhanced each other at low doses, but when the con-
centration of one of themwas increased it blocked the response to
the other. When MMQO was added, there was synergy with both
compounds, but when the dose of hit 1 or 4 was increased in the
presence of the other one, it became inhibitory (Fig. 4H). Mainly,
hit 4 (class 1) blocks the synergy between hit 1 and MMQO, sug-
gesting that MMQO and class 1 hits act on the same target.
HIV-1 reactivation in alternative latency cellular models.
Cell clones latently infected with a full-length HIV vector (HIV-
R7/E/GFP) (38) also were tested for reactivation. The effect of
MMQO alone or in combination with other agents (TNF-, TSA,
and 5-azadC) was analyzed in clone J-Lat 15.4 (Fig. 5A). Single
treatments were almost inactive. The reactivation of such clones
required combinations including the demethylating drug
5-azadC, as previously reported (41). MMQO synergized with
treatments such as TNF- plus 5-azadC. In the presence of
FIG 3 MMQO activates HIV at the transcriptional level independently of genome context. (A)MMQO activates latent HIV in different genomic contexts. Cells
of latently infected clones J-Lat E27, A2, and H2 were incubated with increasing concentrations of MMQO for 24 h and analyzed by flow cytometry for
GFP-expressing cells and cell viability. (B) MMQO activates a transfected HIV-1 LTR-luciferase reporter. 293T cells were transfected with an HIV-1 LTR-
luciferase reporter plasmid. One day after transfection, cells were treated with MMQO (80 M), EGF (50 ng/ml), PMA (10 nM), TSA (400 nM), or TNF- (10
ng/ml) for 36 h, followed by cell lysis, protein normalization (5g), and luciferase activity assay. Data are expressed as relative light units (RLU). (C) Time course
response of HIV-1 transcription to MMQO analyzed by RT-qPCR. J-Lat E27 cells were treated with 80 M MMQO for the time indicated, and RNA was
extracted. PMA (10 nM) and TNF- (10 ng/ml) treatments for 12 h were added as controls. HIV transcription was measured by RT-qPCR using primers
corresponding to the HIV 5=LTR (R-gag) and normalizing with GAPDH. The fold change (FC) between treated and untreated cells is shown. (D) MMQO
stimulatesHIV transcription initiation. J-Lat E27 cells were untreated orwere treatedwith 80MMMQO for 24 h, RNAwas extracted, andHIV reactivationwas
measured by RT-qPCR. Amplicons corresponding to the 5=LTR (R-gag), Tat, GFP, and 3=LTR (U3) were used. GAPDH expression was measured for normal-
ization. To compare between different amplicons, qPCRwas performed in parallel from genomicDNA (gDNA).Data are expressed as relative units (RU) (cDNA
amplification/GAPDH)/gDNA amplification in a log scale. A scheme of the HIV minigenome with positions of qPCR primers is shown below. Throughout the
figure data are represented as means SEM (n 3).
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FIG 4 Synergistic activation of HIV expression by combination of MMQO with small molecules known to reactivate latent HIV. (A) MMQO synergizes with
TNF- and PMA on the activation of a latent HIV-1 minigenome. Cells from clone J-Lat E27 were incubated for 36 h with combinations of MMQO (80 M),
TSA (400 nM), PMA (10 nM), TNF- (10 ng/ml), and HMBA (10 mM) and analyzed by flow cytometry. HIV-GFP reactivation is reported as MFI or as the
percentage of GFP-expressing cells for a selection of the treatments together with the percentage of cell viability. (B)MMQO synergizes with prostratin. J-Lat E27
cells were incubated for 36 h with combinations of MMQO (80 M) and prostratin (2 M) and analyzed as described for panel A. Data are represented as
means SEM (n 3). (C) Combined activation of clone J-Lat H2. Cells from clone J-Lat H2 were treated for 36 h with PMA (10 nM), TSA (400 nM), TNF-
(10 ng/ml), HMBA (10 mM), or 5-azadC (5 M) in the absence or presence of MMQO (80 M). HIV-GFP reactivation is reported as MFI. (D) Activation of
HIV-1 with low doses of MMQO and PMA. J-Lat E27 cells were incubated for 16 h with combinations of suboptimal doses of MMQO and PMA and analyzed
as described for panel A. Data are represented as means SEM (n 3). (E) J-Lat E27 cells were treated with increasing concentrations of TNF- (100 to 1,000
ng/ml) or PMA (10 to 160 nM) in the absence or presence (50 or 100M) of MMQO. HIV-GFP reactivation is reported as MFI. (F) J-Lat E27 cells were treated
with increasing concentrations of MMQO (50 to 150 nM) in the absence or presence of HMBA(10 or 20 mM) or TSA (0.4 or 1 M). HIV-GFP reactivation is
reported as MFI. (G) Combinatorial treatment withMMQO and hit 1 or 4. J-Lat E27 cells were treated with increasing concentrations of hit 1 or 4 (5 to 80M)
in the absence or presence (50 or 100M) of MMQO. HIV-GFP reactivation is reported as MFI. Cell viability extracted from the FSC-SSC plots is shown in the
lower panels. (H) Combinatorial treatment with hits 1 and 4 andMMQO. J-Lat E27 cells were treated with increasing concentrations of hit 1 or 4 (10 to 40M)
in the absence or presence (80 M) of MMQO. HIV-GFP reactivation is reported as MFI.
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5-azadC, the response to increasing concentrations of MMQO
was linear for up to 7% of GFP-positive cells at 120 M this drug
(data not shown).
Further, we explored the ability of MMQO to reactivate latent
HIV from two additional widely used cellular models, the human
monocytic andT-lymphoid cell linesU1 andACH-2, respectively,
persistently infected with HIV-1 (Fig. 5B and C). The reactivation
of HIV by MMQO, as analyzed by RT-qPCR, was very limited in
U1 cells but was still similar to that of PHA or TSA. In these cells,
MMQO greatly synergized with an effective treatment such as
TNF- plus 5-azadC. In ACH-2 cells, MMQO upregulated HIV
expression almost 10-fold and was additive to the activation by
TNF- plus 5-azadC.
The reactivation of HIV by MMQO was analyzed in cultured
FIG 5 MMQO reactivates latent HIV from different HIV latency models containing a full-length provirus. (A)MMQO synergizes with treatments that activate
full-length HIV-1 J-Lat cells. Cells from clone J-Lat 15.4 were incubated for 36 h with combinations of TNF- (10 ng/ml), TSA (400 nM), and 5-azadC (5 M)
in the absence or presence of MMQO (80 M) and analyzed by flow cytometry. 5-azadC was added 24 h before other treatments (preincubation). HIV-GFP
reactivation is reported as a percentage of GFP-expressing cells. (B) HIV reactivation from latently infected cell lines U1 and ACH2. U1 and ACH2 cells were
incubated for 6 h with MMQO (80 M), PMA (10 nM), TSA (400 nM), TNF- (10 ng/ml), HMBA (10 mM), or 5-azadC (5 M) as indicated, and RNA was
extracted to assessHIV expression byRT-qPCRusing primers corresponding toHIV 5=LTR (R-gag) and normalizingwithGAPDH.Data are represented relative
to the maximal activation for each cell line. (C) MMQO enhances HIV reactivation by TNF- and 5-azadC in cell lines U1 and ACH2. U1 and ACH2 cells were
incubated for 6 h with TNF- (10 ng/ml) and 5-azadC (5M) or left untreated and were in the absence or presence ofMMQO (80M), and RNAwas extracted
to assess HIV expression by RT-qPCR using primers corresponding to the HIV 5=LTR (R-gag) and normalizing with GAPDH. Data are represented as fold
increases compared to the expression of untreated cells. (D)MMQOreactivation ofHIV-1 frompatients. Twenty to 30million PBMCwere obtained from several
HAART-treated patients (named A to I) and incubated with 80 M MMQO for 36 h or left untreated. RNA was extracted and HIV expression measured by
RT-qPCR using primers corresponding to the HIV 5=LTR (R-gag) and normalizing with GAPDH. Data are expressed as relative units (RU) of HIV/GAPDH
expression. (E) MMQO induces viral particle formation in ACH2 cells. ACH2 cells were incubated for 24 h with MMQO (80 M), PMA, ionomycin (IO), or
prostratin. Cell culture supernatant media were collected 24 and 72 h after the initial addition of drugs and assayed for the Gag-derived p24 HIV protein using
an ELISA tomeasure the production of viral particles. (F)Viral particles induced inMMQO-treatedACH2 cells are infectious.HumanPBMCorACH2 cells were
incubated for 24 hwithMMQO(80M)or prostratin (2M), supernatantmediawere collected, and viral infectivity wasmeasured using TZM-bl indicator cells
harboring an LTR-luciferase reporter system. After 72 h of incubation, cell-associated luciferase activity was determined. Data are expressed as the fold increase
of treated versus untreated cells in relative luciferase units (RLU). Throughout the figure data are represented as means SEM (n 3).
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PBMCs obtained from aviremic,HAART-treated patients. Seeded
PBMCs were treated with MMQO or left untreated for 36 h with-
out prior PHA stimulation, followed by RNA extraction and the
analysis ofHIV expression by RT-qPCR. In at least two out of nine
tested patients, HIV reactivation was clearly detected in MMQO-
treated but not mock-treated PBMCs at the RNA level (Fig. 5D).
Attempts to detect viral particles (Gag-derived p24 antigen) in
media of treated PBMCswere unsuccessful. Instead, infective viral
particles were detected in media of MMQO-treated ACH2 cells,
comparably to treatments with PMAor prostratin, eithermeasur-
ing p24 antigen (Fig. 5E) or using TZM-bl indicator cells harbor-
ing an LTR-luciferase reporter system (Fig. 5F).
MMQO enhances TCR/CD3 stimulation of HIV-1 reactiva-
tion from latency and prevents TCR-induced proliferation in
primaryT cells. It is thought that in latently infectedT cellsHIV-1
can be reactivated in vivo through the stimulation of the T-cell
receptor. The activation of the TCR induces multiple signal trans-
duction pathways, leading to the activation of the HIV transcrip-
tion initiation factors NF-B, NFAT, AP-1, and Sp1, as well as the
regulation of HIV transcriptional elongation. To study the effects
of MMQO on TCR-induced HIV-1 reactivation, Jurkat-LAT-
GFP cells were stimulated with the agonist MAbs -CD3 and
-CD28 in the absence or the presence of MMQO. In Fig. 6A it is
shown that CD3 (1 g/ml) and MMQO activation antagonized
HIV-1 latency, and an additive effect was observed when both
stimuli were provided together. This effect was comparable to the
one observed after stimulation with a pair of -CD3 and -CD28
MAbs which mimic full TCR activation. The effect of MMQO on
CD3-inducedHIV-1 reactivation was dose dependent, reaching a
plateau at a concentration of 80 M (Fig. 6B). At concentra-
tions lower than 80 M, MMQO alone did not antagonize
HIV-1 latency in Jurkat-LAT-GFP cells (data not shown).
Moreover, MMQO clearly synergizes with lower concentra-
tions of MAb -CD3 to reactivate HIV-1 from latency in this
cell model (Fig. 6C).
We next investigated the effect of MMQO on the transcrip-
tional activity of IL-2, TNF-, and LTR promoters in a Tat-
independent manner. We found that in Jurkat cells -CD3 treat-
ment induced the transcriptional activity of the three promoters.
In contrast, MMQO induced HIV-LTR transactivation but failed
to stimulate IL-2 and TNF- gene promoters. Interestingly,
MMQO that enhanced -CD3-induced HIV-LTR transcription
was able to repress CD3-induced IL-2 and TNF- promoter acti-
vation (Fig. 6D). These results prompted us to investigate the ef-
fects of MMQO on the transcriptional activities of minimal pro-
moters containing binding sites for the transcription factors
NF-B, NFAT, AP-1, and Sp1, which are involved in the tran-
scriptional regulation of IL-2, TNF-, and HIV-LTR gene pro-
moters. In Fig. 6E we showed that MMQO alone did not induce
the transcriptional activity of any of these minimal promoters,
enhanced CD3-induced NFAT, NF-B, and AP-1 activation, and
repressed CD3-induced Sp1 transactivation. Similarly, MMQO
alone showed no activity on these reporters when transfected into
HeLa cells, but it synergized strongly with treatments that opti-
mally activated them, namely, TNF- or PMA plus ionomycin
(data not shown).
To identify the biochemical pathways activated by MMQO,
Jurkat cells were stimulated with the MAb -CD3 and MMQO
separately or in combination for 15min, and the phosphorylation
of theNF-B inhibitor IB and theNF-B subunit p65, aswell as
the phosphorylation (activation) of themitogen-activated protein
kinases (MAPKs) JNK12, ERK12, and p38, were investigated
by Western blotting using specific MAbs. CD3 stimulation in-
duced phosphorylation of all proteins analyzed that was clearly
enhanced by costimulationwithMMQO,which by itself activated
JKN12 but not the other pathways (Fig. 6F).Moreover,MMQO
alone was unable to induce IB degradation (data not shown).
To further assess the NF-B and MAPK dependence of CD3
andMMQO-mediated antagonism of HIV latency, we pretreated
Jurkat-LAT-GFP cells with the chemical inhibitors SC-514 (IKK2
inhibitor), PD98059 (MEK1 inhibitor), and SP600125 (JNK in-
hibitor). As depicted in Fig. 6G, JNK inhibition, but not IKK2 and
ERK inhibition, greatly prevented both MMQO- and CD3/
MMQO-induced HIV reactivation, further suggesting that JNK
activation is a central event inMMQOaction onHIV reactivation.
Combined IKK2 andERK inhibition also inhibitedCD3/MMQO-
induced GFP expression (Fig. 6G). The further use of chemical
inhibitors ruled out the participation of calcium signaling/NFAT,
PKC, phosphatidylinositol 3-kinase (PI3K), or p38, among oth-
ers, on MMQO-induced HIV reactivation from J-Lat cells (data
not shown).
We next studied the effects of MMQO on several T-cell activa-
tion events. The SEB activation model was used, since B cells and
macrophages present this superantigen and activate T cells
through the TCR and costimulators. In Fig. 6H it is shown that
DNA synthesismeasured by [3H]TdR uptake in SEB-stimulated T
cells was markedly inhibited by MMQO in a concentration-
dependent manner. Cell cycle analysis in unstimulated T cells
showed that after 4 days in culture most of the cells remained
largely in the G0/G1 phase of the cell cycle (64%), and a significant
percentage (30%) of cells undergo apoptosis that is reflected in the
sub-G0/G1 fraction. Five days following activation with SEB, T
cells were fully cycling and progressed through the S, G2, and M
phases of the cell cycle (34% of the cells), while pretreatment with
MMQO (80 and 160 M) almost completely prevented the entry
of the cells in the S phase of the cell cycle. Moreover, MMQO did
not induce a significant increase in the percentage of hypodiploid
cells (sub-G0/G1), suggesting that at the used doses MMQO did
not induce cytotoxicity or apoptosis in primary T cells (data not
shown).
DISCUSSION
In this study, we used a simple model of HIV-1 latency to screen
small-molecule libraries for new agents that reactivate the dor-
mant virus. Of the compounds identified here, MMQO has been
the most effective and least toxic for Jurkat cells. Although its
reactivating potential is less than that of other known agents, it
may represent a new class of latency-reversing therapy that can be
combined with others to obtain a synergistic effect. Additionally,
although the precise target of MMQO is unknown, it may even-
tually reveal a new plausible intervention into a pathway involved
in the regulation of HIV-1 expression.
The J-Lat model for HIV-1 latency, containing either a mini-
malHIV-1minigenome or a recombinant full-length virus (38), is
useful for the study of the determinants of postintegration latency
associated with distinct integration events (4, 5, 22–24, 41, 48, 49,
59, 80) or to investigate the reactivating potential of several agents
(21, 52, 57, 62, 66, 68, 79, 81, 83). Latency is established due to
transcriptional silencing (i.e., the repression of the integrated
HIV-1 promoter). In vivo, other factors also may be involved, but
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once latency has been established, flushing out the HIV promoter
with external agents is useful to purge the latently infected cells.
Many agents proven to reactivate latent virus in J-Lat cells also
activateHIV-1 in other latencymodels or in PBMCs from infected
patients, such as PMA, prostratin, PHA, HMBA, or HDAC inhib-
itors (7, 43, 82). TNF- is an exception, as it reactivates HIV-1 in
many cell lines but not in other systems based on primary cells
(reviewed in reference 11). In latently infected, resting CD4 T
cells derived from HIV-infected individuals under ART, TNF-
activates viral replication in conjunction with cytokines IL-2 and
IL-6 (14). In this system, NF-B activation by TNF- and binding
to the LTR is not sufficient forHIV-1 activation. TNF-may need
to be combined with inhibitors of DNA methylation for the effi-
cient reactivation of full-length HIV-1 in J-Lat cells (41).
Additional, more sophisticated, in vitro models for HIV-1 la-
tency in primary CD4 T cells have been described (6, 9, 10, 51,
FIG 6 MMQO enhances TCR/CD3 stimulation of HIV-1 reactivation from latency and prevents TCR-induced proliferation in primary T cells. (A and B)
MMQO synergizes with CD3 to reactivateHIV-1 from latency. Jurkat-LAT-GFP cells were stimulated for 18 h on 96-well plates with coated anti-CD3 (1g/ml),
soluble anti-CD28 (0.5 g/ml), and MMQO (160 M) separately or in combination. (B) Jurkat-LAT-GFP cells were stimulated with coated anti-CD3 and
increasing concentrations of MMQO as indicated for 18 h. GFP expression was measured by flow cytometry, and results indicate the percentage of GFP cells.
(C) Jurkat-LAT-GFP cells were stimulated with increasing concentrations of coated anti-CD3 andMMQO at 80M for 18 h. (D) Differential effects of MMQO
on IL-2 andTNF-promoters andHIV-LTR transactivation. Jurkat cells were transiently transfectedwith the plasmids IL-2-Luc, TNF--Luc, and LTR-Luc, and
24 h later they were stimulated with coated anti-CD3 (1 g/ml) in the absence or the presence of either soluble anti-CD28 (0.5 g/ml) or MMQO (160 M) or
with MMQO alone for 24 h. The results are expressed as the percentage of activation considering CD3-induced transactivation as 100% activation. (E) Activity
of MMQO on NF-B-, NFAT-, AP-1-, and Sp1-responsive minimal promoters. Jurkat cells were transfected with NF-B, NFAT, AP-1, and Sp1 luciferase
reporter plasmid DNA and stimulated as described for panel C. Luciferase activity wasmeasured 24 h later after protein normalization. The results are expressed
as the percentage of activation considering CD3-induced transactivation as 100% activation. (F) Effect of MMQO on -CD3-induced NF-B and MAPK
activation. Jurkat cells were stimulated with anti-CD3 and MMQO (160 M) separately or in combination for 15 min, and the levels of phospho-IB,
phosho-p65 (Ser536), phospho-JNK, phospho-ERK, and phospho-p38 were assessed by immunoblotting with specific antibodies and anti-tubulin MAb as a
loading control. (G)MMQOantagonizesHIV-1 latency through the JNKpathway. Jurkat-LAT-GFP cells were treatedwith the ERK inhibitor PD98059 (25M),
IKK2 inhibitor (25 M), and JNK inhibitor SP600125 (1 M) or left untreated, and 30 min later they were stimulated with anti-CD3 plus MMQO (80 M) or
with MMQO alone for 18 h. HIV-GFP reactivation was assessed by flow cytometry, and results indicate the percentage of GFP cells. (H) Effects of MMQO on
T-cell proliferation. Human PBMCs were stimulated with SEB (1 g/ml) in the presence or the absence of increasing concentrations of MMQO for 72 h.
[3H]thymidine incorporationwasmeasured by liquid scintillation counting and is represented as disintegrations perminute (DPM). Throughout the figure data
are represented as means SEM (n 3).
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71, 73, 82). Someof themare not appropriate for high-throughput
screening for activators of latentHIV-1, either because of the short
life span of resting T cells in vitro or because cells aremaintained in
the presence of IL-2 or IL-7, which may activate latent HIV-1 and
alter the quiescent state. In the primary cell HIV-1 latency model
described by Yang and coworkers, cells weremaintained in vitro in
the absence of activating cytokines and were used to screen drug
libraries, obtaining a new compound that reactivated latent
HIV-1, 5-hydroxynaphthalene-1,4-dione (5HN) (82). 5HN acti-
vated HIV-1 by forming reactive oxygen species (ROS) that indi-
rectly activated NF-Bwithout activating NFAT or PKC signaling
and, consequently, without inducing global T-cell activation.
5HN resembles class 1 hits and MMQO, as all contain a double
aromatic ring, but they are chemically divergent. 5HN is a qui-
none that can be enzymatically reduced to a semiquinone radical
that, under aerobic conditions, generates ROS. The role of ROS as
intermediates in activating NF-B and, eventually, expressing
HIV-1 has been described (32, 67). The compounds described
here are unable to support this chemistry and form ROS, so they
might act through a different mechanism. In this line, MMQO
does not promote IB phosphorylation/degradation, activate an
NF-B reporter by itself, or induce IB gene expression (Fig. 6 and
data not shown).Moreover, pretreatmentwith agents that remove
oxygen radicals, such as N-acetyl-L-cysteine (NAC), did not block
HIV reactivation by MMQO, as has been reported for 5HN-
mediated reactivation (data not shown). In conclusion,MMQO is
unable to induce the NF-B pathway by itself, but it induces some
signaling pathway that cross-talks with it, as well as with pathways
affecting AP-1 and NFAT reporter promoters.
A recently reported high-throughput screening using SupT1
cells latently infected with a GFP and secretable alkaline phospha-
tase encoding HIV identified a new activator (AV6) of HIV-1
which required NFAT and synergized with the HDAC inhibitor
valproic acid (55). Our data have shown that MMQO activity on
HIV is independent of NFAT activation, as it was not affected by
cyclosporine or FK506 (data not shown).
Our data suggest that MMQO promotes HIV-1 transcription
initiation and rapid increase in mRNA synthesis, presumably by
stimulating a signaling pathway that directs a transcription factor
to the viral LTR. Because MMQO has synergy with agents such as
PMA or TNF- even at saturating concentrations, we ruled out
the idea that it acts by activating PKC or TNF receptor signaling.
In addition, the absence of the blockage of MMQO effects with
inhibitors of PKC, PI3K, or ERK, among others, eliminated the
participation of these pathways. Another hypothesis we explored
is that MMQO damages DNA and promotes the activation of
cytokines or the ATM/ATR response that, through NF-B, could
stimulate the HIV-1 promoter. It has been previously described
that damaging agents such as UV light may induce the HIV-1
promoter (70, 76). We ruled out the participation of ATM/ATR,
as an inhibitor of this pathway does not block the stimulating
effect of MMQO. Additionally, as already mentioned, the direct
activation of NF-B by MMQO has not been observed in our
experiments. The participation of p38MAPK,which is involved in
reactivation by UV light or cytokines (44), also has been ruled out
by using a specific inhibitor (data not shown).
In some primary models of HIV-1 latency, most common
NF-B inducers did not reactivate latent virus in primary T cells,
but TCR stimulation was very effective at antagonizing HIV-1
latency (6). Therefore, we investigated the activity of MMQO in
the context of TCR activation. Although MMQO is not very po-
tent by itself to reactivate latent HIV-1, this drug efficiently coop-
erates with TCR activation even at the lower concentration tested.
This is of particular relevance becauseMMQOcould be developed
as an antilatency therapy specific for T cells at nontoxic concen-
trations that could be reached at the anatomic sites wherememory
T cells recognize antigen recall. Moreover, we found that the an-
tagonizing activity of MMQO on HIV-1 latency was also en-
hanced in the presence of low concentrations of OKT3. ThisMAb
(Muromonab) is used in clinical practice to prevent the rejection
of organ allografts, but it is also a potent mitogen for T lympho-
cytes, therefore it has been investigated for its ability to purge the
HIV-1 reservoir. In this clinical trial, high concentrations ofOKT3
(5mg/day for four consecutive days) in combination with recom-
binant IL-2 were used, and it was concluded that high-level stim-
ulation might result in a negative outcome because of the deple-
tion of noninfected T cells (29). However, lower concentrations of
OKT3 are well tolerated in humans and can be immunostimula-
tory in cancer patients (63). Thus, a possible combination therapy
based on low concentrations of humanized OKT3 and MMQO
may be of interest for the viral eradication strategies. In this sense,
a major goal for the development of HIV-1 reactivation therapies
is to induce HIV-1 replication from latent reservoirs without in-
ducing polyclonal T-cell activation. Our results fit well with this
principle, as we show thatMMQO inhibits antigen-inducedT-cell
proliferation and the TCR/CD3 induction of IL-2 and TNF-
gene transcription (Fig. 6).
The identification of the exactmechanism of action ofMMQO
requires further research, but our findings indicate that this com-
pound activates signal pathways that differentially regulate IL-2
and HIV-LTR gene transcription. While the mechanisms for IL-2
repression are unknown at the moment, the enhancement of
CD3-induced HIV-1 reactivation can be explained by the coacti-
vation of the NF-B and MAPK pathways. Recently, it has been
shown that T-cell receptor signaling is sufficient to activate tran-
scription elongation in the absence of Tat by a mechanism that
involves the ERK-dependent activation of P-TEFb (42). Thus, it is
likely that MMQO favors transcription initiation by activating
NF-B and transcription elongation through the ERK pathway,
overriding the requirement of high levels of HIV-1 Tat protein
that probably are not achievable in latently infected primary
memory cells.
Interestingly, MMQO alone produced JNK phosphorylation
in Jurkat cells. Because MMQO did not show stimulating activity
on an AP1-Luc reporter, it is possible that substrates other than
c-jun are involved in MMQO-induced HIV-1 reactivation. Be-
cause MMQO-activated signals are similar to those induced
through FAS/CD95, such as JNK activation and TCR/CD3 co-
stimulation to activate the NF-B and ERK pathways (36, 56), we
analyzed the potential involvement of the CD95 adaptor protein
FADD on the mechanism of action of MMQO. We generated a
pool of cells containing the HIV-1-GFP minigenome latently in-
tegrated in Jurkat cells stably expressing a dominant-negativemu-
tant of FADD (Jurkat-FADDDN) (36), and we analyzed reactiva-
tion byMMQOand other agonists (data not shown).We found in
thismodel that FADDwas not required for theMMQOactivation
of latent HIV, arguing against this hypothesis.
MMQO synergizes with the class 1 and 2 hits initially identified
in our screening. On the other hand, class 1 and 2 hits have addi-
tive effects at low doses but interfere with each other at higher
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concentrations. When the three compounds are combined, hit 4
(class 1) is a potent inhibitor of the synergism between MMQO
and hit 1 (class 2). Our data suggest that MMQO and class 1 hits
act through the same target, but class 2 compounds function on a
different pathway or on a different component of the same path-
way. Alternatively, all compounds could act on the same pathway,
but its overstimulation could render the pathway inactive and
leave the HIV-1 promoter repressed.
To improve the reactivating activity of MMQO-derived mole-
cules, we performed a second virtual screening to identify com-
pounds pharmacophorically similar to MMQO. From the list of
suggested molecules, we purchased and tested a new set of 15
compounds (Chembridge). A new compound able to reactivate
HIV-1 to levels similar to that of MMQO was obtained,
6-methoxy-2-methylquinolin-4-amine (MMQA) (see Fig. S2 in
the supplemental material). Its structure was a new variation,
different from the class 1 quinolin-8-ol and theMMQOquinolin-
4-ol, and it partially resembles the AV6 compound recently re-
ported elsewhere (55). Due to the structural coincidence between
MMQAand the quinolinaminemoiety of AV6,we cannot rule out
the possibility thatMMQAacts on a different pathway than that of
MMQO. As MMQA showed significant cell toxicity, it was ruled
out as a possibility in this study, and we further focused on
MMQO.
HIV-1 latency has been associated with rare proviral integra-
tion at genome regions unfavorable for promoter accessibility and
transcription initiation, such as centromeric heterochromatin,
gene deserts, or introns of very highly expressed genes (35, 38, 49).
Interestingly, MMQO and the initial hits could reactivate latent
HIV-1 in different J-Lat clones representing these diverse genome
environments. This indicates that the targeted pathway is gener-
ally involved in stimulating transcription initiation from the
HIV-1 promoter, not affecting particular targets that may differ
between integration sites, such as repressive chromatin compo-
nents associated with centromeric heterochromatin, or with the
interfering transcriptional machinery traveling over the proviral
promoter while reading a host gene. Other chromatin-related en-
zymes or components may be repressive in most integration sites,
such as HDACs. Nonetheless, our data suggest thatMMQO is not
acting as an HDAC inhibitor. J-Lat clones generated with a full-
length recombinant HIV-1 vector contain proviruses heavily re-
pressed by DNA methylation (5, 41). Reactivation by agents such
as TNF- or MMQO required cotreatment with DNA methyl-
ation inhibitors such as 5-azadC.
HIV-1 reactivation by MMQO also occurred to a different ex-
tent in the U1 and ACH2 models of HIV latency, harboring pro-
viruses with mutations in their Tat-TAR transcriptional axis, and
MMQO showed an additive or synergistic effect with inducing
treatments, such as TNF-plus 5-azadC. Finally,MMQOwas also
able to induce HIV-1 expression in blood cells obtained from
some of the infected patients analyzed. Considering the extremely
low proportion of latently infected cells in PBMC (estimated to
be106 in lymphocytes) (13), the lack of response in someof the
patients may be due to stochastic effects. Taken together, these
findings show thatMMQO is able to reactivate latent HIV-1 from
diverse environments and in different models obtained withmin-
imal or complete viral genomes.
The discovery of MMQO as a new inducer expands the reper-
toire of available strategies to be combined with standard ART to
reduce the reservoir of latent HIV-1. Further studies are required
to identify the precise target of the agents described here, and their
capacity to reactivateHIV-1may be improved by combining com-
putational and chemical approaches. After additional cellular
models of HIV latency have been tested, preclinical trials could be
undertaken to further assess the viability of a therapy based on
MMQO combined with physiological or pharmacological TCR/
CD3 stimulation.
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